Senescent cells secrete a combination of factors collectively known as the senescence-associated secretory phenotype (SASP). The SASP reinforces senescence and activates an immune surveillance response, but it can also show pro-tumorigenic properties and contribute to age-related pathologies. In a drug screen to find new SASP regulators, we uncovered the mTOR inhibitor rapamycin as a potent SASP suppressor. Here we report a mechanism by which mTOR controls the SASP by differentially regulating the translation of the MK2 (also known as MAPKAPK2) kinase through 4EBP1. In turn, MAPKAPK2 phosphorylates the RNA-binding protein ZFP36L1 during senescence, inhibiting its ability to degrade the transcripts of numerous SASP components. Consequently, mTOR inhibition or constitutive activation of ZFP36L1 impairs the non-cell-autonomous effects of senescent cells in both tumour-suppressive and tumour-promoting contexts. Altogether, our results place regulation of the SASP as a key mechanism by which mTOR could influence cancer, age-related diseases and immune responses.
mTOR regulates MAPKAPK2 translation to control the senescence-associated secretory phenotype Senescence is a stable arrest induced in damaged or ageing cells 1 . Senescent cells undergo changes in their transcription, chromatin organization and metabolism 2 . They also secrete a group of factors collectively termed the senescence-associated secretory phenotype (SASP), which influence the tumour microenvironment and the homeostasis of aged tissues 3, 4 . For example, the SASP of senescent fibroblasts promotes the epithelial to mesenchymal transition (EMT) of epithelial cancer cells 3 , while also enhancing their tumorigenic potential 5 . In contrast, the SASP can induce senescence 4, 6, 7 and activate the immune system to keep neoplastic cells in check 8 . The SASP is regulated transcriptionally by NF-κB and CEBP-β and its expression is sustained by redundant autocrine feedback loops 7, [9] [10] [11] . In addition, signalling through p38α mitogen-activated protein kinase (MAPK14) (ref. 12 ) and the persistent DNA damage response associated with senescence 13 contribute to SASP induction 14 .
Cells undergoing oncogene-induced senescence (OIS) augment their secretory phenotypes by coordinating protein synthesis and autophagy in the TOR-autophagy spatial coupling compartment (TASCC; ref. 15 ). Disruption of mammalian target of rapamycin (mTOR) recruitment to the TASCC affects interleukin-6 (IL-6) and IL-8 production 15 . However, it is still unclear how mTOR ultimately regulates this and to what extent mTOR affects the SASP. mTOR integrates inputs from nutrient and growth signals to control processes such as protein and lipid synthesis and autophagy 16 . To regulate protein synthesis, mTOR phosphorylates the eukaryotic translation initiation factor 4E (EIF4E)-binding proteins (4EBPs) and S6 kinases (S6K1 and S6K2) 17 . Whereas S6K1/2 phosphorylation controls translation initiation and elongation 18 , phosphorylation of 4EBPs promotes cap-dependent translation by preventing 4EBP binding to EIF4E (ref. 19) . As well as controlling overall translation rates, mTOR differentially regulates the translation of transcripts with 5 -terminal oligopyrimidine motifs in a 4EBP-dependent fashion 20 . Rapamycin-treated mice show a significant increase in lifespan 21 and resistance to age-related pathologies, and mTOR inhibitors are being used for cancer therapy. Elucidating how mTOR regulates the SASP may aid understanding of the aetiology of these complex disorders.
RESULTS mTOR inhibition prevents the induction of the SASP
To screen for drugs blunting the induction of the SASP, we used IMR90 cells bearing an ER:RAS fusion protein (IMR90 ER:RAS) as a model of OIS. Treatment of IMR90 ER:RAS cells with 4-hydroxytamoxifen (4OHT) activates RAS, inducing senescence and the SASP (ref. 6 ). The expression of six robustly induced SASP components, which are known to mediate the paracrine effects of senescent cells 6 , was used as readout of the screen (Fig. 1a ). Amongst compounds preventing SASP induction, we identified antagonists of IL-1 or NF-κB signalling ( Fig. 1b and Supplementary Table 1 ), as previously described 6, 10, 11 . We also identified that rapamycin, a natural mTOR inhibitor, prevented the SASP of cells undergoing OIS (Fig. 1b ). It has been suggested that rapamycin inhibits the SASP (refs 22,23) , but to what extent and how is unclear. The effects of rapamycin were validated using short hairpin RNAs (shRNAs) targeting mTOR, other mTOR inhibitors (Torin1 and NVP-BEZ235) and further fibroblast strains (BJ and HFFF2; Fig. 1c,d and Supplementary Fig. 1a ). mTOR depletion or rapamycin treatment also diminished the SASP during replicative senescence ( Fig. 1e ) and in response to γ-irradiation (Fig. 1f ). The ability of mTOR inhibition to impair the SASP was also observed at the protein level ( Supplementary Fig. 1b,c) .
To understand to what extent mTOR regulates the SASP, we analysed the secretome of senescent cells by mass spectrometry (MS; refs 24,25) . Amongst the SASP factors (secreted at higher levels in senescent than normal cells) detected by MS, mTOR depletion reduced secretion by at least 20% for half of them (41/78) ( Fig. 1g and Supplementary Table 2 ). Inhibiting mTOR with rapamycin, Torin1 or NVP-BEZ235 had similar effects ( Supplementary Fig. 1d ). Importantly, amongst the SASP components downregulated we identified IL-6, IL-8 and other functionally important factors (Supplementary Table 2 ) 6,7,9 . As rapamycin extends the lifespan of mice 21 , and the ablation of senescent cells improves age-related diseases 26, 27 , downregulating the SASP could contribute to the benefits observed in rapamycin-treated old mice. Analysing liver samples, we observed an upregulation of the SASP during ageing (Fig. 1h) . Interestingly, 22-month-old mice treated with rapamycin from 9 months of age 21 expressed lower levels of the SASP than their untreated age-matched counterparts (Fig. 1h ). Altogether, our results indicate that mTOR regulates the SASP. mTOR inhibition affects the SASP without reversing the senescence growth arrest Inhibition of mTOR has been shown to impair the senescence phenotype, but there is conflicting evidence as to whether it also reverses the senescence growth arrest 22, 28, 29 . Blocking mTOR signalling in IMR90 ER:RAS cells resulted in fewer senescence-associated beta-galactosidase (SA-β-Gal)-positive cells and decreased levels of other senescence markers, such as p16 INK4a and p21 CIP1a . However, mTOR inhibition did not rescue the growth arrest ( Fig. 2a and Supplementary Fig. 2a-c ). This may be explained by the well described antiproliferative effects caused by mTOR inhibition 30, 31 . In fact, rapamycin significantly decreased the levels of cyclin D3 in IMR90 ER:RAS senescent cells ( Supplementary Fig. 2d ).
In the experiments described above, we simultaneously added mTOR inhibitors and 4OHT ( Fig. 2a ). To exclude that SASP downregulation was a consequence of cells not dividing or being prevented to enter into senescence by mTOR inhibition, we conducted experiments in which we treated IMR90 ER:RAS cells with mTOR inhibitors only once OIS was established (Fig. 2b) . In this setting, Torin1-mediated inhibition of mTOR signalling ( Supplementary  Fig. 2e ) also resulted in downregulation of the SASP and reduced SA-β-Gal staining but did not rescue cell growth (Fig. 2b,c and Supplementary Fig. 2f ). Therefore, mTOR inhibition can dissociate the senescence growth arrest from SASP induction.
Regulation of translation initiation by 4EBP controls the SASP
mTOR phosphorylates several downstream effectors, with 4EBPs being one of the best studied. 4EBPs control global translation rates but also differentially regulate the translation of specific messenger RNAs (ref. 20) . Interestingly, expression of a dominant negative 4EBP1 mutant (4EBP1-DN; Supplementary Fig. 3a ) inhibited the SASP in response to both OIS and γ-irradiation ( Fig. 3a-c and Supplementary  Fig. 3a,b) .
To exclude the possibility that mTOR inhibition affected the SASP by non-specifically blocking translation, we compared the effects of Torin1 and cycloheximide (CHX, which blocks translational elongation). Whereas senescent cells treated with Torin1 remained arrested ( Fig. 3d ), CHX treatment triggered rapid cell death. These results ( Fig. 3d ) suggested that the effects caused by mTOR inhibition during senescence were not due to a global translational shutdown. To investigate how mTOR inhibition affects the rate of protein synthesis during senescence, we took advantage of a quantitative fluorogenic assay using the methionine analogue L-azidohomoalanine (AHA; ref. 32 ). The global translation rate increased during OIS and, in agreement with previous studies 20 , treatment with Torin1 greatly reduced de novo protein synthesis. However, overall translation was still comparable to that of non-senescent cells. In contrast, CHX almost completely shut down protein synthesis (Fig. 3e) .
The above results suggest that mTOR and 4EBP1 might control the SASP by regulating the translation of specific mRNA(s). To investigate this, we fractioned ribosomes from senescent cells treated with Torin1 or vehicle for 3 h ( Supplementary Fig. 3c ). We assessed the distribution of mRNAs in polysome and non-polysome (monosome) fractions ( Fig. 3f and Supplementary Fig. 3d,e ). In cells treated with Torin1, the distribution of mRNAs for canonical mTOR targets (for example, EEF2 or RPS20) shifted almost completely to the 'monosome' , non-translated fractions (Fig. 3f ). This was not the case for the mRNA of a housekeeping gene such as glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (Fig. 3f ). The polysome association of the mRNAs of most SASP components analysed decreased slightly ( Fig. 3f and Supplementary Fig. 3e ), consistent with the general effect of Torin1 on translation. Amongst the SASP components analysed, the mRNAs coding for IL-8 and IL-1α suffered the largest drop in polysome association on Torin1 treatment (Fig. 3f ). Nonetheless, more e a b c 32 
Mouse livers
Vector Vector mTOR.3 shRNA +4OHT - TFPI2  IL8  ANGL4  TSP1  TPA  CYTC  IL6  INHBA  MMP3  HGF  CXCL5  SCG2  TSP2  CO3  LIF  CSF2  PAI2  CXCL2  BMP2  IBP2  PVR  FAM3C  IBP7  DCBD2  UROK  NPTX1  MRC2  CHID1  PRS23  NRG1  SEM6D  LTBP3  MMP1  TGFB1  CSF3  PXDN  IBP5  LOXL2  TR11B  ES1  TIMP1  SPON2  PTX3  ARPC4  IGF2  CATL1  STC1  CYTN  QPCT  BOLA2  MINP1  CAB45  ANXA2  FINC  NTRI  GDF15  CXCL3  HSP13  WNT5A  MMP10  COIA1  SRPX2 than 60% of the mRNA for all SASP components tested remained associated with polysomes under acute mTOR inhibition in OIS ( Fig. 3f and Supplementary Fig. 3e ), suggesting that mTOR might regulate the translation of other target(s) to control the SASP. +4OHT Figure 2 mTOR inhibition impairs the SASP without reversing the senescence growth arrest. (a) mTOR inhibition results in decreased SA-β-Gal activity but cells remain arrested. IMR90 ER:RAS cells were induced to undergo senescence by 4OHT treatment. Cells were treated with the indicated drugs from day 0. BrdU incorporation was measured at days 4 and 7 after induction and SA-β-Gal activity was determined at day 7. Data are mean ± s.d. from n = 6 (BrdU) and n = 4 (SA-β-Gal) independent experiments. Representative images for SA-β-Gal activity staining are shown. Scale bar, 40 µm. (b) Inhibition of mTOR after senescence induction downregulates SAβ-Gal activity without reversing growth arrest. Senescence was induced in IMR90 ER:RAS cells by 4OHT treatment for 7 days. At that stage, senescent cells were treated with 25 nM Torin1. BrdU incorporation was monitored at the indicated times and SA-β-Gal activity was measured at day 13. Data are mean ± s.d. n = 4 independent experiments. Representative images for SAβ-Gal activity staining are shown. Scale bar, 40 µm. (c) Inhibition of mTOR after senescence induction downregulates the SASP. IMR90 ER:RAS cells were treated as in b. The expression of the indicated SASP components was monitored by qRT-PCR 13 days after 4OHT induction (6 days after adding Torin1). Data are mean ± s.d. from n = 3 independent experiments. All statistical significances were calculated using two-tailed Student t-tests, * * * P < 0.001; * * P < 0.01; * P < 0.05; NS, non-significant. For raw data, see Supplementary Table 7 .
mitogen-activated protein kinase-activated protein kinase 2 (MAP-KAPK2) (also known as MK2) increased during senescence but declined on mTOR inhibition ( Fig. 4a and Supplementary Table 3 ). MAPKAPK2 is located downstream of p38α MAPK (ref. 34 ), a known SASP regulator 12 . Immunoblotting confirmed that MAPKAPK2 phosphorylation was blunted on mTOR inhibition, but it also revealed reduced levels of MAPKAPK2 and, to a lesser extent, of p38α MAPK (Fig. 4b ). However, whereas p38α activity was not affected by mTOR inhibition, as shown by unchanged phosphorylation of its substrate ATF2, phosphorylation of HSP27 (a MAPKAPK2 substrate) decreased significantly ( Fig. 4b ). As p38α and MAPKAPK2 interact physically, reciprocally controlling their stability 34 , decreased MAPKAPK2 could explain the reduced p38α levels. Interestingly, global ribosome profiling has suggested that mTOR can control MAPKAPK2 translation 20, 35 . Accordingly, the percentage of MAPKAPK2 mRNA (but not the mRNAs for MAPK14 or the upstream kinase MKK6) bound to polysomes dropped markedly on acute mTOR inhibition in OIS ( Fig. 4c and Supplementary Fig. 4a ). As transcript levels for MAPKAPK2 or MAPK14 (that encodes for p38α) remained unchanged when mTOR signalling was blocked ( Fig. 4d ), Supplementary Fig. 3c,d . Graphs show the percentage of the indicated mRNAs present in actively translating polysome fractions. EEF2 and RPS20 transcripts are mTOR canonical targets. GAPDH is insensitive to mTOR inhibition. Data are mean ± s.d. n = 3 independent experiments. All statistical significance was calculated using two-tailed Student t-tests, * * * P < 0.001; * * P < 0.01; * P < 0.05; NS, non-significant. For raw data, see Supplementary Table 7 .
our results suggested that mTOR specifically regulates MAPKAPK2 translation during senescence.
To confirm this, we analysed MAPKAPK2 translation by giving an AHA-biotin pulse followed by streptavidin pulldown and immunoblotting ( Fig. 4e and Supplementary Fig. 4b ). Acute mTOR inhibition decreased de novo synthesis of MAPKAPK2 (∼80%) to an extent similar to that observed for mTOR canonical targets. In contrast, de novo translation of different SASP components (IL-8, . (e) mTOR inhibition strongly impairs de novo translation of MAPKAPK2. After 7 days of 4OHT treatment, IMR90 ER:RAS cells were treated as shown in the scheme. AHA-containing proteins were biotinylated and further purified using streptavidin beads. The expression of de novo synthesized proteins was analysed by immunoblot with the indicated antibodies (right) and quantified (left) (n = 3). (f) IMR90 ER:RAS cells were infected with a 4EBP1-DN. The expression of 4EBP1, MAPKAPK2 and p38α was measured by immunoblot 7 days after 4OHT addition. (g) IMR90 ER:RAS cells were treated with 100 nM MK2 inhibitor III. The expression of the indicated SASP components was monitored by qRT-PCR 7 days after 4OHT induction (n = 3). All statistical significance was calculated using two-tailed Student t-tests, * * * P < 0.001; * * P < 0.01; * P < 0.05; NS, non-significant. All error bars represent means ± s.d. n represents number of independent experiments. For b, e and f representative images from three independent experiments are shown. Unprocessed original scans of blots are shown in Supplementary Fig. 9 . For raw data, see Supplementary Table 7 . IL-6  IL-8   ANXA2  AXA2L  NTNG1  ANGL4  CATL1  NTRI  PVR  SIL1  OAF  SFRP1  QPCT  TIMP1  MMP1  B3GN1  AGRIN  HSP13  CXCL6  LAMA5  B4GT1  TSP2  SRPX2  PRS23  IGF2  FAM3C  SRPX  SCG2  MRC2  PTX3  NRP1  GALA  HGF  CYTC  LTBP1  UPAR  IBP7  CCL20  ARPC4  BMP2  CSF2  FUT11  LIF  CXCL3  BOLA2  CSF3  NAMPT  ERAP1  IL11  SEM6D  GROA  CXCL5  IL6  TFPI2  TR11B  CCL2  IBP5  VEGFA  DCBD2  TSP1  STC1  UROK  VEGFC  NRG1  5NTD  LTBP3  MMP3  WNT5A  AREG  LOXL2  MMP10  INHBA  IL8  TPA  PXDN  POSTN  GDF15  TGFB1  IBP2  CXCL2  SPON2  CAB45  COIA1  NPTX1 . For raw data, see Supplementary Table 7 .
IL-1β
IL-1β and MMP1) decreased only by 25-35%, comparable to the effect observed for housekeeping genes such as those coding for GAPDH and β-actin ( Fig. 4e ). These differential effects were in contrast with CHX treatment, which similarly suppressed de novo synthesis of all analysed proteins ( Fig. 4e ).
To further address whether mTOR controls MAPKAPK2 translation, we monitored MAPKAPK2 expression and mTOR signalling during OIS. As reported previously 36 Supplementary  Fig. 9 . For raw data, see Supplementary Table 7 .
( Supplementary Fig. 4c ). Remarkably, MAPKAPK2 protein levels and mTOR signalling significantly correlated across the analysed time course ( Supplementary Fig. 4c ). In addition, overexpression of 4EBP1-DN strongly downregulated MAPKAPK2 protein levels (Fig. 4f ), and pharmacological inhibition or knockdown of MAPKAPK2 prevented SASP induction ( Fig. 4g and Supplementary Fig. 4d ). Altogether, our results suggest that mTOR controls the SASP through 4EBP1-mediated regulation of MAPKAPK2 translation. fibroblasts, infected with the indicated vectors, were co-injected with 5PT squamous carcinoma cells in partially immunocompromised Rag1 −/− mice. Tumour volume was measured after 5-6 weeks. Student's t-test was carried out to compare mice injected with irradiated versus non-irradiated fibroblasts for every single condition. n = 5 mice per group. Data presented are mean ± s.d. * * * P < 0.001; * P < 0.05; NS, non-significant. For raw data, see Supplementary Table 7 .
Phosphorylation of ZFP36L1 by MAPKAPK2 regulates the SASP Phosphoproteomics identified that a known MAPKAPK2 substrate, ZFP36L1 (ZFP36 ring finger protein-like 1, also known as Tis11b or BRF1), was phosphorylated at Ser 54 during OIS. Importantly, this phosphorylation was impaired on mTOR inhibition (Supplementary Fig. 5a and Supplementary Table 3 ). ZFP36L1 is a Zn-finger protein that destabilizes mRNAs by binding to AU-rich elements (AREs) in their 3 untranslated regions (3 -UTRs; ref. 37 ). ZFP36L1 targets mRNAs of several cytokines for degradation 38 40 ). The effect of mTOR inhibition on ZFP36L1 phosphorylation during OIS was corroborated using antibodies against ZFP36L1 (which detected a band shifted in senescent cells) and a phosphospecific pZFP36L1 S203 antibody 41 (Fig. 5a ). Importantly, ZFP36L1 phosphorylation during OIS was sensitive to MAPKAPK2 inhibition ( Fig. 5b and Supplementary Fig. 5b ). Inhibition of mTOR also affected ZFP36L1 protein levels ( Fig. 5a and Supplementary Fig. 5c ), probably as a result of phosphorylation-regulated proteasomal degradation 40 as ZFP36L1 translation did not change on mTOR inhibition ( Supplementary Fig. 5d ). Next, we expressed either a wild-type ZFP36L1 or a nonphosphorylatable mutant version resistant to inactivation by MAPKAPK2 (ZFP36L1 S54A,S92A,S203A , ZFP36L1 Mut ) in IMR90 ER:RAS cells ( Fig. 5c and Supplementary Fig. 5d ). Expression of ZFP36L1 Mut markedly reduced the levels of the SASP transcripts, but it also rescued cell proliferation and inhibited senescence (Fig. 5d,e and Supplementary Fig. 5e,f) . ZFP36L1 belongs to a family of RNA-binding proteins that also includes TTP and ZFP36L2. Interestingly, expression of ZFP36L2 Mut , and to a lesser extent TTP Mut , also compromised SASP induction ( Supplementary  Fig. 5g -i). Although we only identified ZFP36L1 phosphorylation during OIS ( Supplementary Table 3 ), we cannot exclude a similar Supplementary Fig. 8d ) and further quantified. MAPKAPK2 levels were normalized to GAPDH expression, and 4EBP1 phosphorylation (p4EBP1 T37/T46 ) was referred to normalized 4EBP1. Mouse livers were obtained 6 days after Nras G12V induction. (n = 4 mice per condition.) (e) Quantification of Nras+ (left), p21 Cip1 + (centre) and p16 Ink4a + (right) cells on liver sections 9 days after Nras G12V injection (n = 5 mice per condition). Representative images of the sections quantified in the top panel are shown in the bottom. Scale bar, 40 µm. (f) Liver sections were collected 6 days after Nras G12V injection and stained for the CD3 (T cell marker) and F4/80 (macrophage marker). (Carrier, n = 5 mice; rapamycin, n = 4 mice; ×200.) Arrows indicate clusters of infiltrating immune cells, which suggest clearance of senescence hepatocytes. Quantification of positive cells mm −2 (CD3+ T cells) or percentage of positive area (F4/80+ macrophages) is included in the images. Scale bar, 50 µm. All statistical significances were calculated using two-tailed Student t-tests, * * * P < 0.001; * * P < 0.01; * P < 0.05; NS, non-significant. All error bars represent means ± s.d. For raw data, see Supplementary Table 7 .
role for TTP or ZFP36L2 in SASP regulation. Proteomic analysis showed that ZFP36L1 Mut downregulates the majority of the SASP (60/89, Fig. 5f and Supplementary Table 2 ). A significant overlap was observed between the factors downregulated (but not those upregulated) by mTOR inhibition and by ZFP36L1 Mut expression ( Fig. 5g and Supplementary Fig. 5j,k) , highlighting a role for ZFP36L1 in mediating SASP regulation by mTOR. In addition, the factors downregulated on mTOR inhibition or by ZFP36L1 Mut expression presented more AREs in their 3 -UTRs than expected or than factors upregulated by mTOR ( Fig. 5h and Supplementary Fig. 5l ), as predicted using the ARE score 42 . Finally, cells in which ZFP36L1 was knocked down repressed the SASP less efficiently in response to mTOR inhibition ( Fig. 5i ), suggesting that mTOR regulates the SASP through ZFP36L1.
ZFP36L1 is a direct regulator of the SASP
Gene set enrichment analysis of IMR90 ER:RAS cells expressing ZFP36L1 Mut confirmed that, as well as inhibiting the SASP, ZFP36L1 Mut also prevented senescence ( Supplementary Fig. 6a ). Consistent with ZFP36L1 targeting mRNAs enriched in AREs in their 3 -UTRs, greater downregulation by ZFP36L1 Mut correlated with a higher ARE score (Fig. 6a ). To investigate whether ZFP36L1 regulated the SASP directly, we generated a doxycycline-inducible ZFP36L1 Mut construct, and induced its expression after OIS establishment (Fig. 6b ). Genes with a high ARE score (such as IL-8 or IL-1β) were strongly downregulated as early as 6 h after ZFP36L1 Mut induction, suggesting a direct event. Downregulation of genes with a lower ARE score (such as MMP3 or MMP10) took at least 24-48 h, suggesting secondary effects, while expression of SASP components unaffected by ZFP36L1 Mut (such as TIMP1) did not change ( Fig. 6c and Supplementary Fig. 6c ). Using this system, increased 5-bromodeoxyuridine (BrdU) incorporation was also observed 24 h after ZFP36L1 Mut induction ( Supplementary Fig. 6d ).
ZFP36L1 has been shown to target the CDKN1A mRNA (coding for p21 CIP1 ; ref. 43 ). Indeed, ZFP36L1 Mut induction during OIS resulted in an early and strong downregulation of CDKN1A but not other cyclindependent kinase inhibitors (such as p16 INK4a , Fig. 6d ). This could explain how ZFP36L1 Mut rescues growth arrest. To determine if the effect of ZFP36L1 Mut on the SASP can be uncoupled from the bypass of the senescence arrest, we expressed a CDKN1A mRNA lacking its UTRs, which is resistant to ZFP36L1 Mut -mediated downregulation. Remarkably, restoration of p21 CIP1 levels impaired the ability of ZFP36L1 Mut to rescue the senescence phenotype (Fig. 6e,f and Supplementary Fig. 6e ,f) but not its ability to downregulate the SASP (Fig. 6g ). Therefore, ZFP36L1 Mut regulates the SASP as part of a direct pathway involving mTOR, 4EBP1 and MAPKAPK2 (Fig. 6h) .
The mTOR/ZFP36L1 pathway controls the pro-tumorigenic effects of the SASP As inhibiting mTOR only suppresses a subset of SASP components, we investigated whether this was sufficient to affect the paracrine effects of senescence, starting with its pro-tumorigenic abilities. The SASP of senescent fibroblasts can promote EMT, increasing the tumorigenic potential of epithelial cancer cells 3, 5 . While the conditioned medium (CM) of senescent fibroblast induced EMT in T47D breast cancer cells, CM of IMR90 ER:RAS in which mTOR was depleted or inhibited did not ( Fig. 7a and Supplementary  Fig. 7a,b ). A similar result was observed when expressing 4EBP1-DN or ZFP36L1 Mut (Fig. 7a) . Importantly, the CM of cells expressing both ZFP36L1 Mut and a non-degradable CDKN1A also failed to promote EMT ( Supplementary Fig. 7c ). Similarly, while CM of fibroblasts that had undergone irradiation-induced senescence enhanced the invasive properties of the squamous cell carcinoma 5PT cell line, fibroblasts with depleted mTOR levels, or expressing ZFP36L1 Mut , were less capable of doing so (Fig. 7b) . In nude mice, co-injection of 5PT cancer cells with irradiated, senescent, fibroblasts resulted in increased tumour growth (Fig. 7c) . In contrast, co-injection with irradiated fibroblasts expressing ZFP36L1 Mut or shRNAs against mTOR failed to enhance tumour growth (Fig. 7c ).
mTOR inhibition also blunts the tumour-suppressive effects of the SASP Next we analysed how mTOR inhibition affects the tumoursuppressive properties of the SASP. We previously showed that CM of senescent cells can induce 'paracrine senescence' in normal cells 6 . In contrast, CM of IMR90 ER:RAS cells with depleted mTOR or overexpressing 4EBP1-DN or ZFP36L1 Mut (in the presence or absence of CDKN1A) failed to induce paracrine senescence ( Fig. 8a and Supplementary Fig. 8a ). mTOR knockdown also diminished the ability of IMR90 ER:RAS cells to induce senescence of normal IMR90 cells when co-cultured ( Supplementary Fig. 8b ).
Finally, we took advantage of a mouse model in which OIS is triggered in hepatocytes through transposon-mediated transfer of oncogenic Nras (Nras G12V ). Nras G12V expression induces senescence and the SASP triggers an immune response that eliminates preneoplastic hepatocytes 44 . To investigate whether rapamycin affects the SASP, senescence and immune surveillance, we pre-treated mice with rapamycin for three days before injecting the Nras G12V transposon and treated with rapamycin for nine more days (Fig. 8b) . Treatment with rapamycin impaired SASP induction ( Fig. 8c and Supplementary Fig. 8c ) and correlated with reduced MAPKAPK2 levels ( Fig. 8d and Supplementary Fig. 8d ). Nine days after Nras G12V expression, there was a higher percentage of Nras-positive cells but fewer p21 Cip1 and p16 Ink4a -positive hepatocytes in rapamycin-treated mice (Fig. 8e ). As treatment with rapamycin did not affect the number of Nras-positive cells shortly after Nras G12V injection ( Supplementary  Fig. 8e ), the most plausible explanation for the differences in Nras + hepatocytes is that the impaired SASP resulted in decreased immune surveillance and elimination. Consistent with this, we detected reduced infiltration of T cells, B cells, NK cells and macrophages in the livers of mice treated with rapamycin ( Fig. 8f and Supplementary  Fig. 8f ). To exclude the possibility that the observed differences were due to rapamycin pre-treatment inhibiting entry into senescence, we treated mice with rapamycin only after senescence was triggered and obtained similar results ( Supplementary Fig. 8g ). Although we cannot rule out a direct effect of rapamycin on the immune cells, the above results suggest that mTOR inhibition can control senescence and the SASP during cancer initiation in vivo.
DISCUSSION
The inhibition of mTOR suppresses the SASP by specifically downregulating MAPKAPK2 translation. In OIS MAPKAPK2 phosphorylates and inhibits ZFP36L1, an mRNA-binding protein involved in ARE-mediated decay that targets SASP components. Therefore, it follows that mTOR inhibition results in reduced mRNA levels and not only decreased translation of the SASP. Bioinformatic predictions and our experimental results suggest that several SASP components are directly targeted by ZFP36L1. The question remains as to whether SASP components degraded with delayed kinetics are less efficient ZFP36L1 Mut targets or whether a hierarchical model could be proposed in which the downregulation of a few specific SASP components (such as IL-8 or IL-1β) results in decreased levels of others owing to the disruption of autocrine feedback loops. Our results identify an mTOR-dependent pathway required to control the SASP. Whether a similar mechanism operates in non-senescent cells with elevated mTOR signalling remains to be investigated.
In contrast with mTOR inhibition, a constitutively active ZFP36L1 Mut not only prevented SASP induction but also rescued growth arrest. The explanation for their different effects on cell growth is twofold. mTOR inhibition causes an arrest, partially explained by downregulation of cyclin D3 (ref. 31 ; Supplementary Fig. 2d ). In contrast, ZFP36L1 Mut can target p21 Cip1 for degradation ( Fig. 6d ). Despite these differences, mTOR and ZFP36L1 converge to regulate the SASP as demonstrated by the impaired ability of rapamycin to suppress the SASP in cells lacking ZFP36L1 (Fig. 5j) .
As most SASP factors used as readouts in our screen are NF-κB targets, it could be argued that our screen was biased to identify regulators of the 'pro-inflammatory' SASP. However, we found that a subset of both NF-κB-dependent and independent SASP components is regulated on mTOR inhibition or ZFP36L1 Mut expression. Importantly, regulating this subset of the SASP is sufficient to impair both its tumour-suppressive and tumour-promoting functions. Late in cancer or during ageing 45 , the pro-inflammatory SASP can be harmful. Therefore, inhibiting mTOR may suppress pro-tumorigenic effects or help to maintain tissue homeostasis by alleviating the chronic, low-grade inflammation observed in aged tissues 45 . However, the inhibition of mTOR can also compromise senescence and its associated immune surveillance, being potentially detrimental during the early stages of cancer.
How individual SASP components contribute to all these processes and whether the MAPKAPK2/ZFP36L1 pathway described here is involved in the outcome of mTOR inhibition in vivo requires further investigation. Nevertheless, our findings provide evidence of a critical integration between mTOR and senescence. This may partly explain the reported beneficial effects of rapamycin in cancer and age-related diseases, and may also yield a potential avenue to improve the treatment and/or prevention of these pathologies.
METHODS
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METHODS
Cell culture, retroviral and lentiviral infection. HEK-293T, HEK-293 Gag Pol,
IMR-90, BJ, HFFF2, 5PT and T47D cells were obtained from the American Type Culture Collection and tested for mycoplasma contamination regularly. No cell lines used here are listed in the database of commonly misidentified cell lines maintained by ICLAC and NCBI Biosample. The cell lines have not been authenticated. Cells were maintained in DMEM (Invitrogen) supplemented with 10% FBS (Sigma), 1% antibiotic-antimycotic solution (Invitrogen). 5PT cells were cultured in keratinocyte growth medium or KGM (α-MEM medium supplemented with 2.2 g l −1 sodium bicarbonate, 10 ng ml −1 EGF, 5 µg ml −1 insulin, 0.4 µg ml −1 hydrocortisone, 10% FBS, 1% L-glutamine and 1% adenine). Cell number and viability measurements were determined using the Guava Viacount reagent (Millipore) and the Guava Cytometer (Millipore). Retroviral and lentiviral infection were carried out as previously described 46, 47 .
Chemical compounds and treatments. Chemical compounds and concentrations
used in the drug screen are summarized in Supplementary Table 4 . Unless stated otherwise, 10 nM rapamycin (Tocris), 25 nM Torin1 (Tocris), 0.5 nM NVPBEZ-235 (LC Laboratories) and 100 nM MK2 inhibitor III (Calbiochem) were added simultaneously with 125 nM 4OHT on the day of induction or just after irradiation. In the replicative senescence experiments, cells were treated for 1 week before analysis. In all cases, drugs were re-added every 48 h.
Plasmids. pLNC-ER:RAS has been described previously 7 . MSCViresGFP-4EBP1-4A (4EBP1-DN) was obtained from Hans-Guido Wendel (MSKCC), and subsequently subcloned in MSCVpuro retroviral vector. pBabepuro ZFP36L1wt, Flag-ZFP36L1wt, ZFP36L1Mut, Flag-ZFP36L1Mut, Flag-ZFP36L2wt, Flag-ZFP36L2mut, Flag-TTPwt and Flag-TTPmut were synthesized by GenScript. To generate a doxycycline-inducible Flag-ZFP36L1Mut transgene, we PCR-amplified it from pBabepuro Flag-ZFP36L1Mut to include BstBI and XbaI restriction sites (forward, 5 -CGTTCGAAGCCATGGACTACAAGGACG-3; reverse, 5 -GCTC TAGAGGCTTAGTCATCTGAGATGGAAAGTC-3) and we then subcloned it into a modified pLenti CMVtight eGFP Puro (w771-1) obtained from Addgene. pGIPZ-based shRNA vectors targeting mTOR were from Sigma. p21 coding sequence was PCR-amplified using MSCVpuro p21 CDS as a template (forward, 5 -CGGGATCCGCCATGTCAGAACCGGCT-3; reverse, 5 -GCGTCGACG GCTTAGGGCTTCCTCTTG-3) and subcloned into a pWZLBlast backbone. For de novo generation of ZFP36L1 and MAPKAPK2 miR-E shRNAs, 97-mer oligonucleotides coding for the respective shRNAs (ref. 48 ) were PCR-amplified using the primers miRE-Xho-fw and miRE-EcoOligo-rev and cloned into pRRL lentiviral vector. The RNA interference sequences used are listed in Supplementary  Table 5b .
BrdU incorporation, crystal violet staining and SA-β-Gal staining. These methods have been previously described elsewhere 6, 46, 47, 49 .
CM. The indicated cells (2.5×10 6 ) were seeded in a 10 cm dish and incubated for 7 days with 125 nM 4OHT in DMEM with 0.5% FBS. The CM was then collected, centrifuged at 4,000g and filtered through a 0.2 µm pore filter. The resulting CM was mixed with DMEM 40% FBS in a proportion of 3 to 1 to generate CM containing 10% FBS. When CM was collected from cells treated with chemical compounds, the cells were incubated with the drugs until day 4, and at this point the cells were thoroughly washed with PBS and the media was replaced. The cells were kept drug free for the next 3 days until CM collection.
Gene expression analysis.
Total RNA was extracted using Trizol reagent (Invitrogen) and the RNeasy isolation kit (Qiagen). DNAs were generated using SuperScript II reverse transcriptase (Invitrogen), dNTPs and random hexamers. PCR reactions were carried out in a Real-Time PCR Detection System (BioRad) using Power SYBR Green Master Mix or TaqMan Universal PCR Master Mix (Applied Biosystems). Expression was normalized to ribosomal protein S14 (RPS14) expression in human cell extracts and to 18S ribosomal RNA or GAPDH in mouse tissues. Primer sets and TaqMan probes used are listed in Supplementary Table 5a . Mouse tissue samples were weighed and ground to a fine powder in liquid nitrogen. The RNA was then extracted and processed as described above.
RNA-seq. RNA-seq libraries were prepared from 500 ng of total RNA using the Illumina TruSeq mRNA stranded library prep kit (Illumina) according to the manufacturer's protocol. Library quality was checked on a Bioanalyser HS DNA chip and concentrations were estimated by Qubit measurement. Libraries were pooled in equimolar quantities and sequenced on a HiSeq 2500 using paired end 100-base pair reads. At least 40 million reads passing filter were achieved per sample, and they were processed using standard procedures.
Invasion assays. Transwell invasion assays were carried out using 8 µm pore size polycarbonate Transwell filters (Costar) coated with Matrigel diluted 1:2 in α-MEM. The cells that migrated to the lower chamber were trypsinized and counted on a CASY counter (Scharfe System) 3 days after plating onto the upper chamber.
IF and high content analysis
. IF was carried out as previously described 46 using the antibodies and dilutions listed in Supplementary Table 6 . Image acquisition was carried out using an automated high throughput microscope (IN Cell Analyzer 2000, GE Healthcare). A minimum of 1,000 cells was acquired for each sample per duplicate. High content analysis was carried out using the IN Cell Investigator software (version 3.2; GE Healthcare), as described elsewhere 6, 46, 47, 50 . Briefly, DAPI staining of the nuclei was used to identify cells. The nuclei were segmented using top-hat segmentation, specifying a minimum nucleus area of 100 µm 2 . To define the cell area, a collar segmentation approach was used with a border of 1 µm around DAPI staining, or alternatively a multiscale top-hat was used to detect cytoplasmic intensity for a given staining. Each cell was assigned a nuclear intensity value (and cell intensity value when applicable) for the specific protein being studied. A histogram of the intensity values of all the cells in a sample was produced, and this was used to set a threshold filter to determine positive and negative expressing cells. Alternatively, normalized intensity values for a given staining were obtained by subtracting the intensity of the secondary antibody alone (background intensity) from raw intensity values. Normalized intensity values were used to calculate fold changes among different conditions. Error bars and P-values were derived from independent biological replicates. The antibodies used for the analysis were validated with robust controls (shRNAs, overexpression or drug inhibition) to assess their specificity. Statistical analysis of IF data was conducted using the GraphPad software Prism (version 6.0b).
De novo protein synthesis experiments. Global protein synthesis was detected by
using the Click-iT AHA Alexa Fluor 488 Protein Synthesis HCS Assay (Invitrogen) according to the manufacturer's protocol. Briefly, IRM90 ER:RAS cells were grown in the absence or presence of 4OHT for 7 days and then pre-treated for 2 h with the indicated drugs (the last 30 min in L-methionine-free media to deplete methionine reserves). At this point 100 µM Click-iT-labelled AHA was added to the media. 30 min later cells were washed and fixed. Following incubation with Click-iTreactive Alexa Fluor 488 dye and DAPI staining, images were acquired and analysed as previously described for IF and high content analysis. The represented intensity values were obtained by subtracting the intensity value of cells that were not grown in the presence of AHA (but were incubated with Click-iT-reactive Alexa Fluor 488 dye) from raw intensity values. To analyse nascent synthesis of specific proteins, we also used Click-iT AHA. IMR90 ER:RAS cells were grown with 4OHT for 7 days and then pre-treated for 2 h with 250 nM Torin1, 10 µg ml −1 CHX or DMSO (the last 30 min in L-methionine-free media to deplete methionine reserves). At this point 50 µM AHA was added to media and cells were kept in culture for 4 h and then immediately lysed in 1% SDS, 50 mM Tris-HCl buffer. After quantification, 600 µg of protein per condition were processed using the Click-iT protein analysis detection kit (biotin alkyne) according to the manufacturer's protocol. Resulting samples, in which AHA has been biotinylated, were loaded into Sephadex SpinTrap G-25 columns (GE Healthcare) to get rid of free biotin. Afterwards, samples were diluted to 0.5% SDS and further subjected to immunoprecipitation with streptavidin beads to purify biotinylated (de novo synthesized) protein. Samples were eluted with Laemmli buffer and subjected to western blotting. As a control we used extracts from untreated cells, which incorporated AHA, but were not incubated with biotin alkyne.
Irradiation. To induce SASP induction by ionizing radiation, the indicated cells
were γ-irradiated (5 Gy) and analysed at the indicated times.
Immunoblot. Protein extracts from cell lines were processed and analysed as previously described 47 . Tissues were removed and homogenized in lysis buffer (50 mM Tris pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% w/v Triton X-100) supplemented with complete protease inhibitor cocktail and phosphatase inhibitors (1 mM sodium orthovanadate, 5 mM sodium fluoride and 2 mM β-glycerophosphate). The antibodies and dilutions used are listed in Supplementary  Table 6 . pZFP36L1 S203 antibody has been previously described 41 . Immunoblots were quantified using ImageJ.
Analysis of mRNA distribution in polysomes. IMR90 ER: RAS fibroblasts (10 6 ) were seeded in 10 cm dishes (16 plates) and incubated for 6 days with 125 nM 4OHT. Cells were then treated with vehicle (eight plates) or 250 nM Torin1 (eight plates) for 2 h. 10 min before lysis, cells were treated with 100 µg ml −1 cyclohexamide, washed in ice-cold PBS plus 100 µg ml −1 cyclohexamide at 4 • C and then lysed in polysome lysis buffer (0.3 M NaCl, 15 mM MgCl 2 , 15 mM Tris-HCl (pH 7.6), 1% Triton X-100, 0.1 U µl −1 RNAsin (Promega), 100 µg ml −1 cyclohexamide, 1 µg ml −1 heparin) at 4 • C. Cells were centrifuged at 9,300g for 10 min at 4 • C, and the resulting supernatant was layered onto a 5 ml continuous sucrose gradient (15-50% sucrose in 0.3 M NaCl, 15 mM MgCl 2 , 15 mM Tris-HCl (pH 8), 100 µg ml −1 cyclohexamide, 1 µg ml −1 heparin, 0.1 U µl −1 RNAsin). Gradients were centrifuged at 260,000g for 2 h in an SW41-Ti rotor at 4 • C, and then sampled using a Teledyne ISCO density gradient fractionation system with continuous monitoring at 254 nm. 0.5 ml fractions were collected (20 fractions per sample) and extracted in 3 volumes of Trizol LS reagent (Invitrogen). The resulting 20 fractions (per sample) were pooled into 10 sequential fractions and the RNA extracted with the RNeasy isolation kit (Qiagen). The complementary DNAs were prepared and PCR reactions were carried out as mentioned above. mRNA amounts in each fraction were plotted as a percentage of the total mRNA in the sample. Secretome characterization. The indicated cells were seeded in two 10 cm dishes per condition (4 × 10 6 cells per plate) with vehicle or 125 nM 4OHT in phenol red free DMEM with no FBS. After 6 days, CM was collected, centrifuged at 4,000g and filtered through a 0.2 µm pore filter. The resulting media CM was then concentrated about 100-200-fold by ultrafiltration using the Vivaspin 20 5,000 MWCO by centrifugation at 5,000g . At this stage, the protein concentration was determined by Pierce 660 nm protein assay reagent (Pierce 1861426). 100 µg of protein for each sample was reduced and alkylated with dithiothreitol and iodoacetamide respectively, then digested overnight with immobilized trypsin at 37 • C. Reversephase solid phase extraction was used to desalt the sample, and tryptic peptides were eluted from the column using 50% acetonitrile containing 0.1% formic acid. Peptides were lyophilized in a Speed Vacuum centrifuge then solubilized in 0.1% trifluoroacetic acid before automated loading onto an Acclaim PepMap 100 trap column (100 µm × 2 cm) using an Ultimate 300 RSLC instrument. Peptides were separated on an Acclaim PepMap RSLC analytical column (75 µm × 25 cm) and eluted directly into the nanoelectrospray source of an LTQ-Orbitrap Velosmass spectrometer (ThermoFisher). Separation was carried out using a 120 min gradient from 5 to 45% mobile phase B (80% acetonitrile +0.1% formic acid; mobile phase A 98% water, 2% acetonitrile, 0.1% formic acid). The mass spectrometer was operated in data-dependent acquisition mode for the top 10 collision-induced dissociation acquisitions.
Phosphoproteomic analysis.
Phosphoproteomic analysis was carried out as described previously 51 with some modifications 52 . Three 10 cm dishes of IMR90 ER:RAS cells were seeded (2 × 10 6 per plate) per condition. 7 days after 4OHT induction, cells were lysed in urea lysis buffer (8 M urea, 20 mM HEPES) containing phosphatase inhibitors and, after diluting to less than 2 M urea, 400 µg proteins were digested using immobilized trypsin overnight at 37 • C. The resulting peptides were desalted by reverse-phase solid phase extraction in 1 cm 3 Oasis cartridges (Waters) using the manufacturer's instructions with the exception that peptide elution was with 1 ml of 2 M glycolic acid, 50% acetonitrile, 5% trifluoroacetic acid. Eluted peptides were spiked with 50 µl TiO 2 (50% slurry) that was then collected by centrifugation and washed with washing solution (2 M glycolic acid, 50% acetonitrile, 5% trifluoroacetic acid) three times. Phosphopeptides were eluted from TiO 2 using ammonium hydroxide and dried in a Speed Vacuum centrifuge until the time of analysis. Samples were solubilized and separated by nano-liquid chromatography as per the proteomic analyses, but a top 10 MSA (multistage activation) method was utilized for increased coverage for neutral loss phosphoproteomic data acquisition.
Analysis of the proteomics and phosphoproteomics data. Raw files were converted to peak lists (in the Mascot Generic Format) using Mascot Distiller (version 2.3.0) and searched using Mascot Server (version 2.3.01) against the SwissProt Uniprot database (2012_03_10) restricted to the relevant taxonomy. Mass windows for tolerance for MS scans were 10 ppm and 600 mmu for MS/MS. Fixed modification of carbamidomethylation of cysteine and variable modifications of oxidation of methionine and glutamine to pyroglutamate conversion were permitted. For phosphoproteomic data further variable modifications of phospho(S/T/Y) were included. Mascot result files were parsed using a Perl script written in house that uses the Mascot Parser files provided by Matrix Science. The threshold for accepting peptides as being positively identified was set at an expectancy score of 0.05. Pescal was then used to automate the construction of the extracted ion chromatogram of all peptides identified in an experiment across all samples being compared, as described previously 25, 53 . Data were normalized by dividing each peptide intensity by the sum of all peptide intensities within a sample. Fold changes were calculated by averaging the normalized intensities of peptides within a sample group and dividing these by the intensities of the control group. Fold changes were then log transformed before calculation of significance using an unpaired t-test. The resulting P-values were corrected for multiple testing using the Benjamini-Hochberg procedure.
Kinase substrate enrichment analysis. KSEA was carried out as described before 33 . Briefly, a script written in VBA was used to link identified phosphorylation sites to those listed in the phosphoSite database 54 and to calculate values of enrichment by subtracting means of all fold changes from the means of those belonging to predefined kinase substrate groups. The significance of enrichment was calculated using a Z-test.
Heat maps and ARE score. Secreted proteins were identified as previously described 6 , and only those secreted factors increased in RAS-expressing cells were further analysed. Protein measurements were then mean normalized using the 'scale' function in R and visualized as heat maps using MultiExperiment Viewer (MeV). The significance of the observed ARE score was computed using permutation tests. The observed mean of the ARE score is compared with the distribution of mean values generated by permutation (number of permutations = 100,000). The P-values are estimated as the relative frequency of simulated means greater than the observed mean ARE score of the group. The significance of overlap between groups was computed by hypergeometric test.
In vivo hepatocyte senescence experiments. 5 mg ml −1 rapamycin stock solution in 100% ethanol was prepared. This stock solution was first diluted in sterile 10% PEG400/8% ethanol and in an equal volume of sterile 10% Tween 80 for a final concentration of 10 mg/100 ml. Rapamycin (1 mg kg −1 ) was delivered once every 3 days by oral gavage. Treatment started at day −3 or +3 and continued until the animals were killed. At day 0 hydrodynamic tail vein injection of a transposonbased Nras expression plasmid together with an expression plasmid for the Sleeping Beauty 13 transposase 44 was carried out. At day 3, 6, 9 or 12 (depending on the experiment) the animals were killed and livers collected. Samples were fixed and subjected to immunohistochemistry/IF analysis. In brief, after deparaffinization of paraffin slides, slides were blocked, incubated with the primary antibody at 8 • C overnight, washed, incubated with the appropriate secondary antibody for 1 h at room temperature, washed, mounted and sealed. Five high power fields were counted on two liver sections from each mouse liver (×200, >200 counted cells per field). No statistical method was used to predetermine sample size. For all animal experiments, only mice in a C57BL/6 background were used (equal gender distribution in randomized groups). [16] [17] [18] [19] [20] week old mice were used. For the experiments in which mice were treated with carrier or rapamycin before hydrodynamic tail vein injection, 14 carrier-treated mice and 13 rapamycin-treated mice were used. For the experiment in which mice were treated with carrier or rapamycin 3 days after hydrodynamic tail vein injection, four mice per group (carrier or rapamycin) were used. The investigators were not blinded to allocation during experiments or outcome assessment. All mice were maintained under pathogenfree conditions in accordance with the institutional guidelines of the Helmholtz Centre for Infection Research and Hannover Medical School. Experiments have been approved by the German legal authorities.
Samples from rapamycin-treated old mice. Mice used here have been previously described 55 . Briefly, all mice were UM-HET3, bred as the progeny of CByB6F1 mothers and C3D2F1 fathers. Encapsulated rapamycin was administered from 9 months of age to mice at doses of 14 ppm embedded in the food (calculated on the basis of the equivalent mass of non-encapsulated rapamycin). The 14 ppm dose has previously been shown to extend lifespan when started at 9 or at 20 months of age 21, 56 . Each donor used here was 22 months of age when killed. No statistical method was used to predetermine sample size. Only female mouse livers were analysed here. Mice were equally randomized into different treatment groups. The investigators were not blinded to allocation during experiments or outcome assessment. These experiments were carried out following the guidelines of The National Institute on Aging Interventions Testing Program and the University of Michigan.
Immunohistochemistry. Sections (2 µm) of livers (fixed in 4% paraformaldehyde and paraffin embedded) were stained with the indicated antibodies. Incubation in Ventana buffer and staining was carried out on a NEXES immunohistochemistry robot (Ventana Instruments) using an IVIEW DAB Detection Kit (Ventana) or on a Bond MAX (Leica). For quantification of stainings, slides were scanned using a SCN400 slide scanner (Leica) and analysed using Tissue IA image analysis software (Slidepath, Leica).
Experiments on nude mice. 10 6 5PT cells ±3 × 10 6 of the indicated HFFF2 cells were resuspended in 150 µl of supplement-free DMEM; 100 µl of this mix was injected subcutaneously in the flank of partially immunocompromised Rag1 −/− mice. Each mouse was injected in both flanks. [16] [17] [18] [19] [20] week old female mice were used for these experiments. 10 mice were used for the mTOR shRNA experiment (Fig. 7c , centre) and 10 mice were used for the ZFP36L1 experiment (Fig. 7c, right) . Tumour size was measured using an electronic calliper and calculated using the formula 4π/3 × r 3 (radius (r) is calculated from the average diameter, measured as Venn diagrams representing the overlap and significance for the SASP components downregulated or upregulated by multiple mTOR inhibitors and mTOR knockdown. The significance of overlap was computed using hypergeometric test. ** P < 0.01; *P < 0.05. For raw data, see Supplementary Table 7 . Supplementary Fig. 9 . For raw data, see Supplementary Table 7 . Supplementary Fig. 9 . For raw data, see Supplementary Table 7 . 5NTD  BOLA2  CCL2  CCL20  CSF2  CSF3  CXCL2  ERAP1  GROA   IL11  IL6  IL8  INHBA  NAMPT  POSTN  TFPI2  TSP1   IL6  IL8 f. SASP genes expression was measured in IMR90 fibroblasts 8 days after irradiation (5 Gy) (n=3). g. Designed TTP and ZFP36L2 phosphomutants. Since MK2 phosphosites for TTP and ZFP36L2 have not been described, we aligned their sequences with that of ZFP36L1 aiming to identify putative MK2 phosphosites. In the case of TTP, homology is low. However, the two known MK2 phosphosites in the murine form of TTP 59 are conserved in the human form. h-i. IMR90 ER:RAS cells were infected with ZFP36L1 wt/mut , ZFP36L2 wt/mut or TTP wt/mut . OIS was induced by 4OHT for 7 days. (h) Protein levels were analysed by immunoblot in presence of MG132 (2 mM, 12h). (i) Expression of SASP genes was measured by qRT-PCR (n=3). j. SASP components detected in our proteomics analysis that are downregulated by mTORinhibitors, shmTOR and ZFP36L1 Mut . k. Venn diagrams representing the overlap between SASP factors upregulated by mTOR inhibitors, shmTOR and ZFP36L1 Mut . l. ARE Score for SASP factors: (left) commonly upregulated by shmTOR and mTOR inhibitors; (right) commonly downregulated by shmTOR, mTOR inhibitors and ZFP36L1 Mut . Plots denote ARE score distribution for 10 5 random combinations of 15 and 17 mRNAs respectively. Statistical significance was calculated by using: (d,e,j and i: Student's t-test) (k: hypergeometric test), (l: permutation tests). *** P < 0.001; ** P < 0.01; *P < 0.05; n.s, non significant. Error bars represent means ± s.d. For b and h data are representative of 3 independent experiments. n represents number of independent experiments. For unprocessed original scans of blots, see Supplementary Fig. 9 . For raw data, see Supplementary Table 7 . Student's T-test was performed to compare the indicated conditions ***P< 0.001; n.s., non significant. For raw data, see Supplementary Table 7 . Supplementary Figure 7 The paracrine protumorigenic effects of senescent cells are sensitive to mTOR inhibition and ZFP36L1 activity. a. mTOR inhibition prevents the EMT induced by the CM of senescent cells. IMR90 ER:RAS cells were treated as indicated in the scheme. CM was collected 7 days after 4OHT induction (mTOR inhibitors were removed from the media at day 4, see methods for details) and T47D cells cultured in that CM. 48h after, E-Cadherin expression was monitored by IF. Fold changes of normalised intensity values (top) and representative pictures are shown (bottom). Data are mean ± s.d. from n=4 independent experiments. Student's T-test was performed to compare treated cells to the control. *** P < 0.001. Scale bar, 40mm. b. Both inhibition of mTOR signalling and expression of ZFP36L1 Mut prevent the upregulation of EMT-specific transcription factors by the CM of senescent cells. IMR90 ER:RAS cells were treated as indicated in the scheme in (a). CM was collected after 7 days. T47D cells were cultured in that CM for the indicated times and processed for RNA extraction. Snail1 and Zeb1 mRNA expression levels were measured by qRT-PCR. In the case of the CM of IMR90 ER:RAS treated with mTOR inhibitors, data are mean ± s.d. from n=3 independent experiments. For the rest of the experiments data are from a representative experiment of n=2 independent experiments. c. CM of both proliferating and arrested ZFP36L1 Mut expressing cells is unable to trigger a complete EMT. The indicated cells were treated with 4OHT for 9 days. Expression of TRE-ZFP36L1 Mut was activated for the last 72h. CM was then collected and T47D cells were cultured in that CM for 48h. E-Cadherin expression was monitored by IF. Fold changes of normalised intensity values (right) and representative pictures are shown (left). Data are mean ± s.d. from n=3 independent experiments.. Student's T-test was performed to compare ZFP36L1 Mut cells to the control (Vector/ Vector). ** P < 0.01. Scale bar, 40mm. For raw data, see Supplementary Table 7 . S1 Effect of the chemical compounds in the mRNA expression levels of key SASP components. 
